Patent foramen ovale closure vs medical therapy for stroke prevention: Meta-analysis of randomized trials andreview of heterogeneity in meta-analyses

Canadian Journal of Cardiology

Volumn 30, Issue 10, 2014, Pages 1216-1224

  Udell, Jacob A ^a   Opotowsky, Alexander R ^b,c   Khairy, Paul ^b,d   Silversides, Candice K ^e   Gladstone, David J ^f   O'Gara, Patrick T ^c   Landzberg, Michael J ^b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; WARFARIN; FIBRINOLYTIC AGENT;

AGE DISTRIBUTION; ANEURYSM; ARTERY EMBOLISM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEVICES; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; PATENT FORAMEN OVALE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; COMPARATIVE STUDY; COMPLICATION; FIBRINOLYTIC THERAPY; FORAMEN OVALE, PATENT; ISCHEMIC ATTACK, TRANSIENT; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTAL OCCLUDER; STROKE; TREATMENT OUTCOME;

FIBRINOLYTIC AGENTS; FORAMEN OVALE, PATENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPTAL OCCLUDER DEVICE; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84908007151     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.05.004     Document Type: Review

References (51)

1. Goldstein L.B., Bushnell C.D., Adams R.J., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:517-584.
2. Lackland D.T., Elkind M.S.V., D'Agostino R., et al. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:1998-2027.
3. Towfighi A., Markovic D., Ovbiagele B. Utility of Framingham coronary heart disease risk score for predicting cardiac risk after stroke. Stroke 2012, 43:2942-2947.
4. Furie K.L., Kasner S.E., Adams R.J., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:227-276.
5. Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124:2458-2473.
6. Kizer J.R., Devereux R.B. Patent foramen ovale in young adults with unexplained stroke. NEngl J Med 2005, 353:2361-2372.
7. Hagen P.T., Scholz D.G., Edwards W.D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984, 59:17-20.
8. Bogousslavsky J., Van Melle G., Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988, 19:1083-1092.
9. Lechat P., Mas J.L., Lascault G., et al. Prevalence of patent foramen ovale in patients with stroke. NEngl J Med 1988, 318:1148-1152.
10. DeRook F.A., Comess K.A., Albers G.W., Popp R.L. Transesophageal echocardiography in the evaluation of stroke. Ann Int Med 1992, 117:922-932.
11. Mas J.L., Arquizan C., Lamy C., et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. NEngl J Med 2001, 345:1740-1746.
12. Leys D., Bandu L., Hénon H., et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 2002, 59:26-33.
13. Handke M., Harloff A., Olschewski M., Hetzel A., Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. NEngl J Med 2007, 357:2262-2268.
14. Kent D.M., Thaler D.E. Is patent foramen ovale a modifiable risk factor for stroke recurrence?. Stroke 2010, 41(Suppl 1):S26-30.
15. Landzberg M.J., Khairy P. Indications for the closure of patent foramen ovale. Heart 2004, 90:219-224.
16. Khairy P., O'Donnell C.P., Landzberg M.J. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Int Med 2003, 139:753-760.
17. Agarwal S., Bajaj N.S., Kumbhani D.J., Tuzcu E.M., Kapadia S.R. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Interv 2012, 5:777-789.
18. Kitsios G.D., Dahabreh I.J., Abu Dabrh A.M., Thaler D.E., Kent D.M. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012, 43:422-431.
19. Opotowsky A.R., Landzberg M.J., Kimmel S.E., Webb G.D. Trends in the use of percutaneous closure of patent foramen ovale and atrial septal defect in adults, 1998-2004. JAMA 2008, 299:521-522.
20. Furlan A.J., Reisman M., Massaro J., et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. NEngl J Med 2012, 366:991-999.
21. Carroll J.D., Saver J.L., Thaler D.E., et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. NEngl J Med 2013, 368:1092-1100.
22. Meier B., Kalesan B., Mattle H.P., et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. NEngl J Med 2013, 368:1083-1091.
23. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
24. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
25. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
26. Taaffe M., Fischer E., Baranowski A., et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer cersus CardioSEAL-STARflex cersus Helex Occluder). Am J Cardiol 2008, 101:1353-1358.
27. Dowson A., Mullen M.J., Peatfield R., et al. Migraine Intervention with STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008, 117:1397-1404.
28. Adams H.P., del Zoppo G., Alberts M.J., et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38:1655-1711.
29. Jauch E.C., Saver J.L., Adams H.P., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013, 44:870-947.
30. Hanley P.C., Tajik A.J., Hynes J.K., et al. Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: report of 80 consecutive cases. JAm Coll Cardiol 1985, 6:1370-1382.
31. Mügge A., Daniel W.G., Angermann C., et al. Atrial septal aneurysm in adult patients: a multicenter study using transthoracic and transesophageal echocardiography. Circulation 1995, 91:2785-2792.
32. Agmon Y., Khandheria B.K., Meissner I., et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 1999, 99:1942-1944.
33. Overell J.R., Bone I., Lees K.R. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55:1172-1179.
34. Homma S., Sacco R.L., Di Tullio M.R., Sciacca R.R., Mohr J.P. Atrial anatomy in non-cardioembolic stroke patients. Effect of medical therapy. JAm Coll Cardiol 2003, 42:1066-1072.
35. Kent D.M., Thaler D.E. The Risk of Paradoxical Embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials 2011, 12:185.
36. Kent D.M., Kitsios G.D. Percutaneous closure of patent foramen ovale: a near-perfect treatment ruined by careful study?. Circ Cardiovasc Qual Outcomes 2012, 5:414-415.
37. Kandzari D.E., Bhatt D.L., Sobotka P.A., et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol 2012, 35:528-535.
38. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
39. Rengifo-Moreno P., Palacios I.F., Junpaparp P., et al. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2013, 34:3342-3352.
40. Pandit A., Aryal M.R., Pandit A.A., et al. Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials. Heart Lung Circ 2014, 23:303-308.
41. Khan A.R., Bin Abdulhak A.A., Sheikh M.A., et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke. JACC Cardiovasc Interv 2013, 6:1316-1323.
42. Ntaios G., Papavasileiou V., Makaritsis K., Michel P. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis. Int J Cardiol 2013, 169:101-105.
43. Pineda A.M., Nascimento F.O., Yang S.C., et al. Ameta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheter Cardiovasc Interv 2013, 82:968-975.
44. Riaz I.B., Dhoble A., Mizyed A., et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. BMC Cardiovasc Disord 2013, 13:116.
45. Kitsios G.D., Thaler D.E., Kent D.M. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke 2013, 44:2640-2643.
46. Wolfrum M., Froehlich G.M., Knapp G., et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart 2014, 100:389-395.
47. Hakeem A., Marmagkiolis K., Hacioglu Y., et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2013, 14:349-355.
48. Spencer F.A., Lopes L.C., Kennedy S.A., Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open 2014, 4:e004282.
49. Kwong J.S., Lam Y.Y., Yu C.M. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. Int J Cardiol 2013, 168:4132-4138.
50. Nagaraja V., Raval J., Eslick G.D., Burgess D., Denniss A.R. Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials. Heart Lung Circ 2013, 22:903-909.
51. Capodanno D., Milazzo G., Vitale L., et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention 2014, 9:1342-1349.